Baseline characteristics
| Characteristic | dMMR (n=36) | pMMR (n=35) |
| Median age (years) (range) | 66 (36–76) | 68 (37–81) |
| ECOG, n (%) | ||
| 0 | 18 (50) | 17 (49) |
| 1 | 15 (42) | 18 (51) |
| 2 | 3 (8) | 0 |
| Grade at diagnosis, n (%)* | ||
| 1 | 9 (26) | 6 (17) |
| 2 | 17 (49) | 3 (9) |
| 3 | 9 (26) | 26 (74) |
| Pathology, n (%) | ||
| Endometrioid | 34 (94) | 20 (57) |
| Serous | 0 | 11 (31) |
| Clear cell | 1 (3) | 1 (3) |
| Others | 0 | 3 (9) |
| Hormone status, n (%) | ||
| ER positive† | 26/28 (93) | 19/29 (66) |
| PR positive† | 21/25 (84) | 14/24 (58) |
| Prior surgery, n (%) | 32 (89) | 31 (89) |
| Prior radiotherapy, n (%) | 27 (75) | 20 (57) |
| Lines of prior systemic treatment for advanced disease, n (%)‡ | ||
| 0 | 21 (60) | 3 (8) |
| 1 | 14 (39) | 22 (63) |
| ≥2 | 1 (3) | 10 (27) |
| Prior chemotherapy, n (%) | ||
| Platinum doublet | 19 (53) | 33 (94) |
| Platinum monotherapy | 3 (9) | 5 (14) |
| Taxane monotherapy | 0 | 3 (8) |
| Doxorubicin/liposomal doxorubicin | 1 (3) | 4 (11) |
| Other chemotherapy | 1 (3) | 2 (6) |
| Previous hormonal therapy, n (%) | 2 (6) | 5 (14) |
| Previous bevacizumab, n (%) | 0 | 2 (6) |
*One missing value.
†Denominators given due to missing values.
‡Excluding hormone, bevacizumab, adjuvant and neoadjuvant chemotherapy received ≥12 months prior to registration.
dMMR, mismatch repair deficient; ECOG, Eastern Cooperative Oncology Group; ER, Estrogen Receptor ; pMMR, mismatch repair proficient; PR, Progesterone receptor.